SCHEMBL8590367

SCHEMBL8590367

COC(=O)c1cnc(C)nc1C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 2/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GAA P10253 2/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
ATM Q13315 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
TSHR P16473 1/20 0.41
LMNA P02545 1/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22120120 0.83 ATM (0.41) NFKB1NFKB2RELAGAAATM
SCHEMBL1014652 0.81 ALDH1A1 (0.45) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL21746957 0.81 NFKB1 (0.55) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL30996914 0.81 RAB9A (0.56) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL1669574 0.81 RAB9A (0.56) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL8552983 0.81 GAA (0.45) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL3618934 0.81 LMNA (0.46) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL3055707 0.79 NPSR1 (0.39) RAB9ANPC1SMN1; SMN2MAPTNFKB1
SCHEMBL2221978 0.79 AHR (0.55) RAB9ANPC1LMNAALDH1A1KMT2A
SCHEMBL1434641 0.78 HPGD (0.61) RAB9ANPC1SMN1; SMN2L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 US disclosed
WO-2023196601-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed
WO-1998051311-A2 DIHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1998-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC11 RAB9A 1958/4885NPC1 2177/4885SMN1; SMN2 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.